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ABSTRACT 1 
Periodontitis is a chronic inflammatory and bone destructive disease. Development of 2 
periodontitis is associated with dysbiosis of the microbial community, which may be caused 3 
by periodontal bacteria, such as Porphyromonas gingivalis. Mast cells are sentinels at 4 
mucosal surfaces and are a potent source of inflammatory mediators, including TNF. The 5 
number of mast cells increases in the gingival tissues of patients with periodontal disease, 6 
although their role in the disease process remains to be elucidated. This study sought to 7 
determine the contribution of mast cells to local bone destruction following oral infection with 8 
P. gingivalis. Mast cell deficient mice (KitW-sh/W-sh) were protected from P. gingivalis induced 9 
alveolar bone loss, with a reduction in anti- P. gingivalis serum antibody titres compared with 10 
wild-type infected controls. Furthermore, mast cell deficient mice had reduced expression of 11 
Tnfα, Il6 and Il1b mRNA in gingival tissues compared with wild-type mice. Mast cell 12 
engrafted KitW-sh/W-sh mice infected with P. gingivalis demonstrated alveolar bone loss and 13 
serum anti- P. gingivalis antibody titres equivalent to wild-type infected mice. The expression 14 
of Tnfα mRNA in gingival tissues of KitW-sh/W-sh mice was elevated following the engraftment 15 
of mast cells, indicating that mast cells contributed to the Tnfα transcript in gingival tissues. 16 
In vitro, mast cells degranulated and released significant TNF in response to oral bacteria; 17 
and neutralizing TNF in vivo abrogated alveolar bone loss following P. gingivalis infection. 18 
These data indicate that mast cells, and TNF, contribute to the immunopathogenesis of 19 
periodontitis and may offer therapeutic targets.   20 
  3 
INTRODUCTION 1 
Periodontitis is a chronic inflammatory disease that destroys the alveolar bone and 2 
connective tissues supporting the teeth. Periodontitis is one of the most prevalent chronic 3 
infectious conditions of humans and is the leading cause of tooth loss among adults 4 
{Kassebaum, 2014 #1}. The ÔkeystoneÕ pathogen, Porphyromonas gingivalis can trigger the 5 
microbial dysbiosis characteristic of periodontitis {Hajishengallis, 2011 #2}, in parallel, the 6 
responding cells and cytokine milieu are central to the tissue destruction {Hajishengallis, 7 
2014 #4959}{Cekici, 2014 #5147}. 8 
Mast cells are sentinels at mucosal surfaces and as such, have a pivotal role in orchestrating 9 
both innate and adaptive immune responses against local microbial challenge {Gordon, 10 
1990 #6}. In vivo studies have demonstrated that mast cells can bind to, phagocytose, and 11 
kill enterobacteria {Malaviya, 1994 #7}, and present bacterial antigens to T cells {Malaviya, 12 
1996 #8}. Mast cells contain a vast array of mediators in their granules, including large 13 
amounts of TNF. In a model of acute septic peritonitis, TNF blockade suppressed the 14 
protective role of mast cells via reduced neutrophil influx {Malaviya, 1996 #10;Echtenacher, 15 
1996 #11}.  16 
Mast cells are integral to anaphylaxis and other allergic disorders but are also implicated in 17 
chronic inflammatory diseases, such as rheumatoid arthritis {Lee, 2002 #12}. Within inflamed 18 
periodontal tissues, increases in both mast cell numbers and the proportion of degranulated 19 
cells in periodontal tissues, associated with severity of periodontitis {Huang, 2014 20 
#14;Lagdive, 2013 #15;Huang, 2013 #16}. Oral mucosal mast cells contain TNF in their 21 
granules. In inflammation, Tnfα mRNA up-regulation, in parallel with mast cell degranulation 22 
and depletion of intracellular TNF, is consistent with continued TNF synthesis and release by 23 
mast cells {Walsh, 1995 #17}. Thus, mast cells may contribute to protection from potentially 24 
invasive bacteria, and to the local and systemic pathological inflammation associated with 25 
periodontitis.  26 
We hypothesised that mast cells, with their armamentarium of inflammatory mediators, could 27 
contribute to the local and systemic pathology associated with periodontitis. We sought to 28 
determine the contribution of mast cells and TNF to local bone destruction following oral 29 
infection with P. gingivalis.  30 
 31 
MATERIALS AND METHODS 32 
Multi-species oral biofilm model 33 
Overnight cultures of Streptococcus mitis NCTC 12261, Streptococcus intermedius NCTC 34 
11324, Streptococcus oralis NCTC 11427, Aggregatibacter actinomycetemcomitans ATCC 35 
43718, Veillonella dispar NCTC 11831, Actinomyces naeslundii ATCC 19039, 36 
Fusobacterium nucleatum ATCC 10953, F. nucleatum subspecies vincentii ATCC 49256, P. 37 
  4 
gingivalis W83 and Prevotella intermedia ATCC 25611 were standardized in artificial saliva 1 
and added sequentially to Thermanoxª coverslips as previously described to generate a 2 
multi-species oral biofilm {Millhouse, 2014 #19}.  3 
Bone marrow derived mast cell culture 4 
Bone marrow was obtained from C57BL/6 mice and bone marrow derived mast cell 5 
(BMMCs) generated as previously described {Kuehn, 2010 #20}. After 4 weeks BMMCs 6 
were assessed by flow cytometry to determine purity and maturity. Cell suspensions were 7 
resuspended in Fc block (CD16/32, eBioscience) containing fluorochrome-labeled antibodies 8 
against FcεR1 and CD117, or similarly labeled isotype controls. Cells were analysed using a 9 
FACscalibur (BD Biosciences), and data analysed using Flowjo (Tree Star Inc., Oregon, 10 
USA). Cell viability, assessed by exclusion of 7-aminoactinomycin, was greater than 98%. All 11 
of the cultured cells were CD117 positive and > 90% were double positive for CD117 and 12 
FcεR1.  13 
For co-culture experiments, mature BMMCs were seeded in 24-well plates at 5x105 14 
cells/well DulbeccoÕs modified eagleÕs medium. BMMCs were cultured adjacent to the 15 
biofilm-covered coverslip attached to a cell culture insert hanging basket as previously 16 
described for 2 h at 37¡C in 5% CO2.  17 
Mast cell degranulation  18 
β-hexosaminidase activity of cell culture supernatants and cell lysates was assessed as a 19 
proxy for mast cell degranulation using a previously described method {Kuehn, 2010 #20}. 20 
The percentage degranulation for each condition was calculated: 100 x (total supernatant 21 
content)/(supernatant + lysate).  22 
ELISA 23 
The concentration of TNF and IL-6 in the BMMC supernatants following co-culture, and of 24 
mast cell protease 1 in mouse serum were measured by ELISA using paired antibodies 25 
(eBioscience) according to the manufacturerÕs instructions.  26 
Murine model of periodontal disease 27 
Female BALB/c (Harlan, UK) or female and male C57BL/6 (bred in house at Strathclyde 28 
University) or age and sex-matched mast cell deficient C57BL/6 KitW-sh/W-sh mice (originally 29 
sourced from Jackson Laboratories, USA and subsequently bred in-house at University of 30 
Strathclyde (Grimbaldeston et al., 2005), were maintained before and during experiments in 31 
specific pathogen-free conditions with ad libitum food and water at the Universities of 32 
Strathclyde or Glasgow. All work was performed in accordance with UK Home Office 33 
regulations and after ethical approval from local research ethics committees and is reported 34 
according to ARRIVE guidelines. Mice were orally infected with 109 colony forming units 35 
(CFU) P. gingivalis W83 (ATCC, Middlesex, UK) in 2% carboxymethylcellulose (CMC) on 4 36 
consecutive days as previously described {Baker, 1994 #22}. Sham-infected control mice 37 
  5 
received CMC alone. At six weeks post-infection (PI), serum, gingival tissues and maxillae 1 
were collected under terminal general anaesthesia. In other experiments, mice received 2 
0.1mg/mouse of anti-TNF antibody or isotype control antibody (both BioLegend), 3 
administered i.p on days -3, 0, 7 and 14 PI. KitW-sh/W-sh mice received 5 x 105 mature 4 
BMMCs/mouse, administered by i.v. on days -28 and 0, as outlined in figure legends. The 5 
mast cells reconstitution was carried out based on previous studies. Following transfer, it 6 
takes 4 weeks to establish mast cells in the tissues, which remain readily detectable 12 7 
weeks after transfer (Grimbaldeston et al).  8 
 9 
Assessment of alveolar bone loss  10 
The maxillae were separated from the skull and gingivae removed. Maxillae were defleshed 11 
and treated as previously described {Baker, 1994 #22}. Images were captured using an 12 
Olympus SZX7 stereo zoom microscope fitted with SC100 digital colour camera. 13 
Measurements of the distance between the cemento-enamel junction (CEJ) and the alveolar 14 
bone crest (ABC) were made using ImageJ software (National Institute of Health, Bethesda, 15 
MD, USA) to assess alveolar bone loss as previously described {Baker, 1994 #22}. 16 
Anti- P. gingivalis ELISAs  17 
Antibody titres to P. gingivalis in the serum samples were measured as previously described 18 
(Malcolm et al., 2015). Antibody titres were calculated as described previously {Gmur, 1986 19 
#24}.  20 
TaqMan¨ real-time PCR 21 
RNA was extracted from periodontal tissues using the RNeasy¨ fibrous tissue kit (Qiagen), 22 
reverse transcribed with High Capacity RNA-to-cDNA (Applied Biosystems¨, Life 23 
Technologies), then mRNA expression analysed by TaqMan¨ real-time PCR, using murine 24 
primers and fluorescent probe assays obtained from Applied Biosystems¨ (Il6: 25 
Mm00446190_m1, Il1b: Mm00434228_m1, Tnfa: Mm00443258_m1, Il17: 26 
Mm00439618_m1, Mpo: Mm01298424_m1, Tpsab1: Mm00491950_m1, Mcpt4: 27 
Mm00487636_g1). Analysis was performed in duplicate, gene expression normalised to 18S 28 
and relative expression of the gene of interest calculated by 2−ΔCT. The data are presented 29 
as the fold change in expression of the gene of interest in the test population e.g. P. 30 
gingivalis infected test group normalized to the control (sham-infected) population. 31 
Statistical analyzes 32 
Data were analyzed by StudentÕs t test or ANOVA with Tukey comparison, as indicated in 33 
the figure legends, using GraphPad Prism 6 (La Jolla, CA, USA).   34 
  6 
RESULTS 1 
Mast cell deficient mice are protected from P. gingivalis mediated alveolar bone loss 2 
To elucidate the role of mast cells in P. gingivalis-induced inflammatory bone loss, wild-type 3 
(WT) or mast cell deficient mice (KitW-sh/W-sh) were orally infected with P. gingivalis 4 
(experiment outline Figure 1A). In WT animals, alveolar bone loss was significantly greater 5 
following P. gingivalis infection compared with sham-infected controls (p<0.001). In contrast, 6 
P. gingivalis infection failed to elicit alveolar bone loss in KitW-sh/W-sh mice (Figure 1B [p<0.05 7 
compared with P. gingivalis-infected WT]). Infection of WT mice with P. gingivalis induced a 8 
robust serum IgG anti-P. gingivalis antibody response (Figure 1Ci), which appeared 9 
dominated by IgG1. Anti-P. gingivalis IgG1 titres were significantly reduced in infected KitW-10 
sh/W-sh compared with infected WT mice (p<0.05, Figure 1Cii). There was no statistically 11 
significant difference in the total IgG in serum of infected KitW-sh/W-sh compared with infected 12 
WT mice.  13 
In the absence of infection, there was greater expression of Tnfα and Il1b in the gingival 14 
tissues of WT mice compared with KitW-sh/W-sh. P. gingivalis infection of WT mice resulted in 15 
increased expression of Il6, Tnfα and Il1b mRNA compared with WT sham-infected controls 16 
(Figure 1D); the difference was statistically significant for Il6 only (Figure 1Dii). After infection 17 
with P. gingivalis, expression of Il6 and Tnfα in the gingival tissues of KitW-sh/W-sh mice 18 
remained significantly reduced compared with P. gingivalis-infected WT mice (p<0.05). 19 
Overall, there appeared to be a reduction in the expression of Tnfα, Il1b and Il6 in the 20 
gingival tissues from KitW-sh/W-sh mice compared with normal WT mice, suggesting that mast 21 
cells may be a significant source of the cytokine transcripts in gingival tissues in both health 22 
and disease. Expression of Il17 was evaluated in the gingival tissues and no significant 23 
differences were found in any of the groups (data not shown).  24 
BMMC engraftment restores alveolar bone loss in P. gingivalis-infected Kit-W mice 25 
The KitW-sh/W-sh mice have compromised kit signalling. Kit (stem cell ligand) is essential for 26 
mast cell development but is also expressed on all hematopoietic stem cells. As a result, kit 27 
mutant mice have a number of immune alterations {Grimbaldeston, 2005 #21}. Although 28 
these are relatively mild in the KitW-sh/W-sh mice compared with other kit mutants, we sought to 29 
investigate whether the reduced alveolar bone loss observed in the KitW-sh/W-sh was mediated 30 
by mast cells and no other phenotypic abnormality of KitW-sh/W-sh mice. Mast cells were 31 
engrafted to reconstitute KitW-sh/W-sh mice with BMMCs prior to infection with P. gingivalis as 32 
outlined (Figure 2A). Engrafted BMMCs were greater than 90% double positive for CD117 33 
(c-kit) and FcεR1 (Figure 2B). As indicators of mast cell engraftment, we assessed serum 34 
mast cell protease 1 (MCPT1), which was readily detectable in WT mice and undetectable in 35 
the serum of KitW-sh/W-sh mice but could be detected, albeit at a low level, in the serum of KitW-36 
sh/W-sh mice engrafted with BMMCs, indicating some mast cell engraftment in KitW-sh/W-sh mice 37 
  7 
at 6 weeks post-BMMC transfer (Figure 2C). Next, we sought to determine whether mast 1 
cells were engrafted within the gingival tissues of KitW-sh/W-sh mice following BMMC transfer. 2 
Mast cell tryptase 1 (TPSAB1) and mast cell protease 4 (MCPT4) were expressed in WT 3 
mice but were either undetectable (TPSAB1) or at the limit of detection (MCPT4) in KitW-sh/W-4 
sh mice (Figure 4Di and ii). In BMMC-engrafted KitW-sh/W-sh mice, both TPSAB1 and MCPT4 5 
mRNA transcripts were detected in the gingival tissues indicating that mast cells had 6 
engrafted to the gingival tissues in these mice. KitW-sh/W-sh mice demonstrate neutrophilia 7 
{Grimbaldeston, 2005 #21}, and therefore we quantified the level of myeloperoxidase 8 
expression in gingival tissues as a surrogate measure of neutrophil infiltration. MPO mRNA 9 
was significantly elevated in the gingival tissues of KitW-sh/W-sh infected mice, compared with 10 
infected BMMC-engrafted KitW-sh/W-sh mice (Figure 2Diii). There was no difference in the level 11 
of MPO mRNA in the gingival tissues of BMMC transferred KitW-sh/W-sh mice compared with 12 
WT mice.  13 
We next sought to investigate the alveolar bone loss in BMMC-engrafted KitW-sh/W-sh mice. As 14 
before, P. gingivalis infection of WT mice induced alveolar bone loss and this phenotype was 15 
attenuated in KitW-sh/W-sh infected mice (Figure 2E [p<0.05]). The disease phenotype was 16 
recapitulated in BMMC-engrafted, P. gingivalis-infected KitW-sh/W-sh mice, with similar alveolar 17 
bone loss to that observed in WT-infected mice (p<0.01 [Figure 2E]). Similarly, the 18 
predominantly IgG1 serum antibody response to P. gingivalis was restored following BMMC 19 
engraftment of KitW-sh/W-sh infected mice (Figure 2F).  20 
The expression of Tnfα mRNA was greater in the gingival tissues of infected KitW-sh/W-sh mice 21 
following BMMC engraftment compared with infected KitW-sh/W-sh that had not received mast 22 
cells (p<0.05 [Figure 2G]). These data indicate that mast cells are a significant source of 23 
Tnfα transcript in gingival tissues. We next examined the ability of BMMCs to produce and 24 
release TNF protein in response to oral bacteria.  25 
Mast cells release TNF and IL-6 in response to oral bacteria 26 
In vitro exposure of BMMC to a periodontitis associated biofilm model induced significant 27 
mast cell degranulation (p<0.05 compared with media control [Figure 3A]), and significant 28 
TNF and IL-6 release (p<0.001, compared with media control [Figure 3B and 3C]), 29 
demonstrating that mast cells can be stimulated to release TNF in response to oral bacteria. 30 
Given that mast cells appear to be a significant source of the Tnfα transcript in vivo, we 31 
hypothesised that TNF release from mast cells may contribute to alveolar bone loss in the 32 
murine model of periodontitis. The role of TNF in periodontitis has long been recognised 33 
{Kinane, 2011 #54} and TNF blockade described in primates {Graves, 1998 #26}. We next 34 
sought to evaluate TNF blockade in this murine model of P. gingivalis-induced alveolar bone 35 
loss.  36 
TNF blockade reduces the severity of P. gingivalis-induced alveolar bone loss  37 
  8 
Anti-TNF or isotype control antibodies were administered to BALB/c mice orally infected with 1 
P. gingivalis (Figure 4A). P. gingivalis-infected isotype control-treated mice demonstrated 2 
significant alveolar bone loss compared with sham-infected controls (p<0.001, [Figure 4B]). 3 
Anti-TNF treatment significantly reduced the severity of alveolar bone loss in P. gingivalis-4 
infected animals compared with infected isotype-control mice (p<0.05). However, this anti-5 
TNF treatment regime failed to completely attenuate alveolar bone loss, which remained 6 
significantly greater than the sham-infected mice (p<0.05). A robust serum IgG anti-P. 7 
gingivalis antibody response was induced following infection with P. gingivalis (Figure 4C), 8 
and these were reduced in mice treated with anti-TNF antibody.   9 
  10 
  9 
DISCUSSION 1 
These data show that mast cell deficiency is associated with protection against the local 2 
tissue destruction of periodontitis. Mast cell deficient KitW-sh/W-sh mice were completely 3 
protected from P. gingivalis-induced periodontitis and mast cells contributed to the 4 
expression of Tnfα in gingival tissues.  5 
To our knowledge, this is the first study to use a mast cell deficient mouse to investigate the 6 
role of mast cells in periodontitis. Previous studies have demonstrated changes in the mast 7 
cell number and degranulation using immunohistochemistry {Huang, 2013 #16;Huang, 2014 8 
#14;Gemmell, 2004 #28}. Moreover, treatment of beagle dogs with lodoxamide ethyl, an 9 
inhibitor of mast cell degranulation reduced the level of alveolar bone loss compared with 10 
untreated controls over a 1 year period {Jeffcoat, 1985 #29}, suggesting therapeutic 11 
targeting of mast cells may be beneficial to prevent periodontal disease. Our data provide 12 
evidence that mast cells and their products are directly involved in periodontal destruction, 13 
further confirmed by engrafting cultured mast cells into KitW-sh/W-sh mice and restoring the 14 
disease phenotype.  15 
Oral administration of P. gingivalis induced a robust serum anti-P. gingivalis antibody 16 
response in WT mice, dominated by Ig1, characteristic of a primarily Th2-mediated response 17 
{Spellberg, 2001 #49}. Th2 immunity is generally associated with mast cell degranulation, 18 
and mast cells have been shown to directly support B cell antibody class-switching {recently 19 
reviewed by \Bulfone-Paus, 2015 #50}. Moreover, KitW-sh/W-sh show compromised IgG 20 
responses following challenge with mucosal adjuvants {Fang, 2010 #52}. Thus, whilst the 21 
trend to reduction in total IgG response and the significant reduction in the IgG1 and IgG2C 22 
anti-P. gingivalis antibody observed in KitW-sh/W-sh infected mice may be a failure of bacterial 23 
colonisation and invasion, data from other studies suggests an important role of mast cells in 24 
driving humoral immunity.  25 
Mast cells, although forming a relatively small proportion of the cellular infiltrate in health or 26 
disease, are widely distributed throughout tissues and constitutively express a broad 27 
spectrum of immune mediators. Based on the reduction in Tnf, Il1 and Il6 transcripts in 28 
healthy gingival tissue in kit-w mice compared with wild type, in these studies, mast cells 29 
may be speculated to constitutively generate some cytokines as previously documented 30 
{Okayama, 1995 #5155}, or respond to the commensal flora with a baseline elevation of 31 
cytokine profile. Rheumatoid arthritis shares similar immunopathogenesis with periodontitis 32 
{Culshaw, 2011 #53}. In vivo studies of mast cells in arthritis have revealed intriguing 33 
inconsistencies dependent on the nature of the mast cell deficiency and subtleties of the 34 
model of disease. Mast cells are redundant for the development of serum-induced arthritis in 35 
KitW-sh/W-sh mice {Zhou, 2007 #31}. This was confirmed using Cpa3Cre mice which are mast 36 
cell deficient and have a reduction in the numbers of basophils but are otherwise 37 
  10 
immunologically normal {Scholten, 2008 #33}. In other studies, mast cells were redundant in 1 
the collagen-induced arthritis model in KitW-sh/W-sh {Pitman, 2011 #34} but Mcpt5Cre-iDTR mice 2 
(another kit-independent model) were in part protected from collagen-induced arthritis 3 
{Schubert, 2014 #35}. These data highlight the complexities of different models of disease 4 
and different models of mast cell deficiency. It would, therefore, be useful to explore the 5 
murine model of periodontitis in a mast cell deficient model that does not rely on impaired kit 6 
signalling.  7 
Although multiple cells implicated in periodontitis can release TNF in response to bacterial 8 
stimulation, mast cells contain particularly abundant preformed TNF {Gordon, 1990 #6}.  Our 9 
observation of reduced Tnfα in mast cell deficient tissues support the hypothesis that mast 10 
cells in periodontal tissues likely contribute to elevated TNF. In periodontitis, TNF can play a 11 
tissue destructive rather than anti-bacterial protective role: in a rat ligature model, 12 
administration of human recombinant TNF exacerbated the inflammatory cell infiltrate and 13 
alveolar bone resorption {Gaspersic, 2003 #36}. Local administration of neutralising anti-TNF 14 
antibodies reduced alveolar bone loss in a primate model of periodontitis {Assuma, 1998 15 
#37;Graves, 1998 #26}. Similarly, p55TNFR-1-KO mice demonstrated less severe bone loss 16 
and reduced inflammation in periodontitis induced by Aggregatibacter 17 
actinomycetemcomitans, although the bone loss was not fully ameliorated {Garlet, 2007 18 
#38}. In the present study, we observed a significant reduction in the serum antibody 19 
response to P. gingivalis following anti-TNF treatment, possibly due to loss of TNF induction 20 
of cell migration, as was reported in p55TNF-1-KO mice. Alveolar bone loss was completely 21 
abrogated in P. gingivalis-infected mast cell deficient KitW-sh/W-sh mice, but neutralising TNF, 22 
as in other studies {Garlet, 2007 #38}, only partially prevented the bone loss. Accurately 23 
defining the contribution of mast cell derived TNF could be achieved by reconstitution of KitW-24 
sh/W-sh mice with TNF knock out mast cells. TNF has often been considered a master 25 
regulator within the cytokine network. TNF also synergises with other cytokines, such as IL-26 
17, amplifying its impact on inflammation {Griffin, 2012 #5152}. In addition to TNF, mast cells 27 
contain an array of pro-inflammatory cytokines in their granules, including IL-1β and IL-6 28 
{Steinsvoll, 2004 #41}, both of which are elevated in periodontitis {Reis, 2014 #43} {Graves, 29 
1998 #26;Graves, 2003 #44}. In the present study, there was marked release of both TNF 30 
and IL-6 from mast cells in vitro following stimulation with periodontal bacteria. Moreover, 31 
there was reduced expression of IL-1β and IL-6 in the gingival tissues of KitW-sh/W-sh mice. 32 
Mast cell deficient mice reconstituted with mast cells demonstrated significantly elevated 33 
Tnfα in their gingival tissues. Surprisingly, the IL1b and Il6 expression were not significantly 34 
influenced by mast cells reconstitution. Whether the mast cell derived IL-1β and IL-6 35 
functions downstream of the mast cell derived TNF remains to be determined. In rheumatoid 36 
arthritis, mast cells expression of IL-17 has been documented in rheumatoid arthritis 37 
  11 
{Hueber, 2010 #3917}. IL-17 drives neutrophil recruitment to the inflamed periodontium {Yu, 1 
2007 #5051}{Eskan, 2012 #4709}. Surprisingly, there were no consistent changes in Il17 2 
expression in the gingival tissues of irrespective of presence of mast cells or infection. 3 
Recently, mast cell derived CXCL1 has been implicated in neutrophil recruitment to sites of 4 
inflammation {Wezel, 2015 #5151}. In addition to cytokines and chemokines, mast cells exert 5 
their effects via serine proteases released from mast cell granules. In humans, mast cell 6 
tryptase expression correlated with the degree of inflammatory infiltrate and the severity of 7 
periodontal disease {Huang, 2013 #16}. These serine proteases are important for the 8 
recruitment of neutrophils to sites of infection {Huang, 1998 #45;Tani, 2000 #46}. This is 9 
particularly pertinent to periodontal diseases in which both hypo- and hyper-recruitment of 10 
neutrophils is associated with bone loss {Hajishengallis, 2014 #47}. Delineating the hierarchy 11 
of the neutrophil and mast cell responses is complex, particularly as mice with mutations in 12 
CD117, such as the Kit-W, show a tendency to neutrophilia ({Grimbaldeston, 2005 #4077}, 13 
and would therefore be more accurately investigated in models of inducible mast cell 14 
deficiency such as the Mcpt5Cre-iDTR mice {Schubert, 2014 #35}. 15 
 16 
Mast cell proteases are important during tissue repair but can also contribute directly to the 17 
destruction of extracellular matrix through degradation of fibrinogen and collagen and 18 
indirectly through the activation of host matrix metalloproteases (MMPs), leading to 19 
attachment loss, propagation of inflammation and exacerbation of bone loss {Steinsvoll, 20 
2004 #41}. Mast cells present in gingival tissues are also reported to directly express MMPs 21 
{Naesse, 2003 #48}. Thus, mast cells have the ability to regulate cellular infiltration and 22 
tissue destruction in periodontal disease by numerous mechanisms.  23 
 24 
Our results provide evidence to indicate that mast cells are a key cell type in the 25 
immunopathogenesis of PD, and these cells contribute to the expression of TNF, a key 26 
mediator in PD. These new data provide further basis for exploring strategies aimed at 27 
preventing and treating PD. Targeting mast cells is of particular interest given the breadth of 28 
existing therapies, targeting both mast cells and TNF, which are already in clinical use for 29 
treating a range of allergic and inflammatory conditions respectively.    30 
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REFERENCES 1 
FIGURE LEGENDS 2 
Figure 1: Mast cell deficient mice are protected from P. gingivalis-induced alveolar 3 
bone loss. 4 
WT or KitW-sh/W-sh mice were orally infected with P. gingivalis (Pg) or vehicle only (Sham) and 5 
were euthanized 42 days post-infection. (A) Overview of experimental model. (B) Bone loss 6 
was measured on defleshed maxillae; values indicate alveolar bone level (ABL) in mice 7 
relative to sham-WT control. (C) Serum anti-P. gingivalis antibody was assessed by ELISA 8 
at the end of the experiment (i) total IgG, (ii) IgG1 isotype and (iii) IgG2c isotype. (D) RNA 9 
was extracted from gingival tissues of WT or KitW-sh/W-sh mice at the end of the experiment.  10 
Expression of (i) Tnfa, (ii) Il6 and (iii) Il1b were assessed by real time PCR.  Data shown are 11 
mean ± SD (n = 7-8 mice/group) * p < 0.05, ** p < 0.01 *** p < 0.001 by ANOVA with Tukey 12 
comparison.  13 
 14 
Figure 2: BMMC engraftment restores alveolar bone loss in P. gingivalis-infected KitW-15 
sh/W-sh mice.  16 
BMMCs were engrafted into KitW-sh/W-sh mice orally infected with P. gingivalis (Pg) or vehicle 17 
only (Sham) and were euthanized 42 days post-infection. (A) Overview of experimental 18 
model. (B) Representative FACs plots showing surface expression of CD117 (c-kit) and 19 
FcεR1 of BMMCs used for engraftment into KitW-sh/W-sh mice. (C) Serum concentrations 20 
(pg/ml) of mast cell protease 1 (MCPT1) assessed by ELISA. (D) RNA was extracted from 21 
gingival tissues of WT or KitW-sh/W-sh mice at the end of the experiment and expression of (i) 22 
mast cell tryptase 1 (Tpsab1), (ii) mast cell protease 4 (Mcpt4) and (iii) myeloperoxidase 23 
assessed by real-time PCR. (E) Bone loss was measured on defleshed maxillae; values 24 
indicate alveolar bone level (ABL) in mice relative to sham-WT control. (F) Serum anti- P. 25 
gingivalis antibody was assessed by ELISA at the end of the experiment (i) total IgG, (ii) 26 
IgG1 isotype and (iii) IgG2c isotype. (G) Expression of (i) Tnfa, (ii) Il6 and (iii) Il1b from the 27 
gingival tissues of KitW-sh/W-sh mice were assessed by real time PCR at the end of the 28 
experiment. Data shown are mean ± SD (n = 4-7 mice/group). *p < 0.05, **p < 0.01 ***p < 29 
0.001 by ANOVA with Tukey comparison. 30 
 31 
Figure 3: Mast cells undergo degranulation and TNFα release following co-culture 32 
with oral bacterial biofilms.  33 
BMMC were cultured for 2 hours with biofilms of oral bacteria or medium only control. (A) In 34 
vitro mast cell degranulation by assessment of β-hexosaminidase activity of cell culture 35 
supernatants and cell lysates (B) TNFα and (C) IL-6 release into supernatants assessed by 36 
ELISA. Data were analysed by StudentÕs t test. *p<0.05, ***p<0.001.  37 
 38 
Figure 4: TNFα blockade reduces the severity of P. gingivalis-induced periodontal 39 
bone loss. 40 
BALB/c mice were orally infected with P. gingivalis (Pg) or vehicle only (Sham), and injected 41 
i.p. with 0.1 mg/ml anti-TNFα or isotype control antibody. Mice were euthanized 42 days 42 
post-infection. (A) Overview of experiment design. (B) Bone loss was measured on 43 
defleshed maxillae; values indicate alveolar bone level (ABL) in mice relative to sham-WT 44 
control. (C) Serum anti-P. gingivalis antibody was assessed by ELISA at the end of the 45 
experiment (i) total IgG, (ii) IgG1 isotype and (iii) IgG2c isotype. Data shown are mean ± SD 46 
(n = 5 mice/group). *p<0.05, **p<0.01 ***p<0.001 by ANOVA with Tukey comparison. 47 
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